|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
By using folic acid (FA) as a recognition element, a total of 100 cancer cells (HeLa) can be distinguished in 1 mL culture medium with 10% FBS.
|
31830181 |
2020 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
By using folic acid (FA) as a recognition element, a total of 100 cancer cells (HeLa) can be distinguished in 1 mL culture medium with 10% FBS.
|
31830181 |
2020 |
|
Degenerative polyarthritis
|
0.020 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations:</b> 3-MA: 3-methyladenine; ACPA: anti-citrullinated peptide antibodies; anti-CCP: anti-cyclic citrullinated peptide antibody; cVIM: citrullinated VIM; BECN1: beclin1; DAPI: 4',6-diamidino-2-phenylindole; FBS: fetal bovine serum; HLA: human leukocyte antigen; IFNG/IFN-γ: interferon gamma; IL6: interleukin 6; IP: immunoprecipitation; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MFI: mean fluorescence index; MHC: major histocompatibility complex; OA: osteoarthritis; PADI: peptidyl arginine deiminase; PepA: pepstatin A; PBS: phosphate-buffered saline; PtdIns3K: phosphatidylinositol 3-kinase; RA: rheumatoid arthritis; SFs: synovial fibroblasts; siRNA: small interfering RNA; VIM: vimentin.
|
31486697 |
2020 |
|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Main pre-specified secondary outcomes included changes in FBS subcomponents and the impact of the knowledge of presence of atherosclerosis as assessed by bilateral carotid/femoral vascular ultrasound.
|
31726193 |
2020 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Main pre-specified secondary outcomes included changes in FBS subcomponents and the impact of the knowledge of presence of atherosclerosis as assessed by bilateral carotid/femoral vascular ultrasound.
|
31726193 |
2020 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Our findings indicate that miR-219 plays a critical role in liver CSCs expansion and sorafenib response, rendering miR-219 as an optimal target for the prevention and intervention of HCC.<b>Abbreviations</b>: HCC: Hepatocellular carcinoma; CSCs: cancer stem cells; DMEM: Dulbecco's modified Eagle's medium; FBS: fetal bovine serum; OS: overall survival.
|
31724462 |
2019 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
F-box only protein 8 (FBX8), as a critical component of the SKP1-CUL1-F-box (SCF) E3 ubiquitin ligases, has been associated with several malignancies through interacting with a member of proteins.
|
31024008 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.030 |
Biomarker
|
disease |
BEFREE |
The results of the current study had shown that after supplementation with 100 mg/day of CoQ<sub>10</sub> for 12 weeks, serum values of FBS, HOMA-IR, TC, LDL-C and ferritin were decreased and values of HDL-C were increased in women with T2DM.
|
29365333 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Our findings indicate that miR-219 plays a critical role in liver CSCs expansion and sorafenib response, rendering miR-219 as an optimal target for the prevention and intervention of HCC.<b>Abbreviations</b>: HCC: Hepatocellular carcinoma; CSCs: cancer stem cells; DMEM: Dulbecco's modified Eagle's medium; FBS: fetal bovine serum; OS: overall survival.
|
31724462 |
2019 |
|
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that miR-219 plays a critical role in liver CSCs expansion and sorafenib response, rendering miR-219 as an optimal target for the prevention and intervention of HCC.<b>Abbreviations</b>: HCC: Hepatocellular carcinoma; CSCs: cancer stem cells; DMEM: Dulbecco's modified Eagle's medium; FBS: fetal bovine serum; OS: overall survival.
|
31724462 |
2019 |
|
Colorectal Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The inactivation of FBX8 negatively correlated with increased levels and stability of GSTP1 in clinical CRC tissues and FBX8 knockout transgenic mice.
|
31024008 |
2019 |
|
Hypertensive disease
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Higher DII scores were associated with higher odds of HTN (OR = 1·13; 95 % CI 1·01, 1·27; P < 0·001), SBP (weighted mean difference (WMD) = 1·230; 95 % CI 0·283, 2·177; P = 0·011), FBS (WMD = 1·083; 95 % CI 0·099, 2·068; P = 0·031), insulin (WMD = 0·829; 95 % CI 0·172, 1·486; P = 0·013), HbA1c (WMD = 0·615; 95 % CI 0·268, 0·961; P = 0·001) and HOMA-IR (WMD = 0·192; 95 % CI 0·023, 0·361; P = 0·026) values compared with lowest DII categories.
|
31708005 |
2019 |
|
Parkinson Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations used:</b> ANOVA: Analysis of variance; Ca: Calcium; CDCl3: Chloroform; COX: Cyclooxygenase; DMSO: Dimethyl sulfoxide; EA: Elidic acid; EDTA: Ethylene diamine tetraacetic acid; ELISA: Enzyme Linked Immunosorbent Assay; ESI-MS: Electron spray mass spectroscopy; FAs: Fatty acids; FBS: Fetal bovine serum; GC: Gas chromatography; 1HNMR: Hydrogen nuclear magnetic resonance; LA: Linoleic acid; MPP+: 1-Methyl-4-phenylpyridinium; MPTP: 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine; MTT: 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide; <i>N. sativa</i>: <i>Nigella sativa</i>; OA: Oleic acid; PA: Palmitic acid; PBS: Phosphate buffer saline; PC12: Rat pheochromocytoma cell line; PD: Parkinson's disease; PDA: Photo diode array detector; PGE2: Prostaglandin E2; TLC: Thin layer chromatography; TMPD: N,N,N',N'-tetramethyl-p-phenylenediamine; USA: United states of America.
|
29200724 |
2019 |
|
Parkinson Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations:</b> BSA: bovine serum albumin; CCCP: carbonyl cyanide m-chlorophenylhydrazone; DMEM: dulbecco's Modified Eagle's Medium; DNP: 2,4-dinitrophenol; FBS: fetal bovine serum; FCCP: carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone; GSH: glutathione; HBSS: Hanks' balanced salt solution; mtKeima: mitochondria-targeted monomeric keima-red; PBS: phosphate buffered saline; PD: Parkinson disease; PINK1: PTEN induced kinase 1; POE SHSY5Ys: FLAG-PRKN over-expressing SHSY5Y cells; SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis; TMRM: tetramethylrhodamine methyl ester; WB: western blot; WT: wild-type; ΔΨm: mitochondrial membrane potential.
|
31060423 |
2019 |
|
Gestational Diabetes
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
The GDM diagnosis was based on 75-g OGTT and FBS tests, respectively, in 24-28 weeks' gestation.Other adverse maternal (e.g.
|
31429355 |
2019 |
|
Gestational Diabetes
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Multivariate logistic regression demonstrated that maternal age ≥ 35 years [OR: 2.91, 95% CI: (1.28-6.62)], high serum FBS [1.10: (1.04-1.16)], HbA1c [1.91 (1.09-3.34)], and ART treatment [2.94: (1.24-6.96)] were independent risk factors for insulin therapy in GDM women.
|
31656196 |
2019 |
|
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The results demonstrated that the glioma neurosphere cells positively expressed stem cell marker SOX2, neuroectodermal stem cell marker Nestin, and also expressed astrocytes marker GFAP and neurons marker β-tubulin III fter FBS-induced differentiation for a week, which proved the glioma neurosphere cells have the self-renewal and multipotential differentiation capacity.
|
28592121 |
2019 |
|
Hyperglycemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Total numbers of studies were as follows: OR for DII and HTN (n 12), OR for DII and hyperglycaemia (n 9), HTN prevalence (n 9), mean (sd) of SBP and DII (n 12), mean (sd) of DBP and DII (n 10), mean (sd) of FBS and DII (n 13), mean (sd) of HbA1c and DII (n 3), mean (sd) of insulin and DII (n 6), mean (sd) of HOMA-IR and DII (n 7).
|
31708005 |
2019 |
|
Acute lymphocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations</b>: NK: natural killer cells; aNK: activated NK cells; EV: extracellular vesicles; ER: endoplasmic reticulum; ALL: acute lymphoblastic leukaemia; FBS: foetal bovine serum.
|
30891164 |
2019 |
|
Vascular calcification
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
To explore the effect of pre- and post-dialysis plasmatic bicarbonate and citrate on vascular calcification, rats aortic rings cultured ex vivo in Minimum Essential Medium containing 0.1% FBS and 45-calcium as radiotracer were used (n = 24).
|
31388059 |
2019 |
|
Metabolic Syndrome X
|
0.010 |
Biomarker
|
disease |
BEFREE |
In morbidly obese adolescents, we identified at least 10 circulating miRNAs, including increased concentrations of miRNAS; miR-142-3p, miR-140-5p, miR-222 miR-143, miR-130, and decreased concentrations of miR-532-5p, miR-423-5p, miR-520c-3p, miR-146a, and miR-15a, which were strongly linked to measures of BMI, WHtR, adipokines; adiponectin, leptin, L/A ratio, and other MS related biomarkers such as FBS, insulin, HOMA-IR, C-peptide, and circulated plasma lipids such as TG, HDL-C, and LDL-C.
|
30309709 |
2019 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Here, we show that loss of FBX8 accelerates chemical-induced colon tumorigenesis.
|
31024008 |
2019 |
|
Central Serous Chorioretinopathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that miR-219 plays a critical role in liver CSCs expansion and sorafenib response, rendering miR-219 as an optimal target for the prevention and intervention of HCC.<b>Abbreviations</b>: HCC: Hepatocellular carcinoma; CSCs: cancer stem cells; DMEM: Dulbecco's modified Eagle's medium; FBS: fetal bovine serum; OS: overall survival.
|
31724462 |
2019 |
|
Miscarriage
|
0.010 |
Biomarker
|
disease |
BEFREE |
Characterization of Dendritic Cell(DC)10 in recurrent miscarriage and recurrent implantation failure.
|
31284267 |
2019 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
In particular hormones found in FBS act globally on cancer cell physiology and influence transcriptome and metabolome.
|
29455394 |
2018 |